DFDA - Trademark Details
Status: 686 - Published For Opposition
Serial Number
88564669
Word Mark
DFDA
Status
686 - Published For Opposition
Status Date
2022-01-04
Filing Date
2019-08-02
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2022-01-04
Attorney Name
Law Office Assigned Location Code
M70
Employee Name
EUBANK, REBECCA A
Statements
Goods and Services
Dosage formulation development and analysis services, namely, pharmaceutical drug development services, testing services for pharmaceuticals, pharmaceutical products development, laboratory research services relating to pharmaceuticals, or testing, inspection or research of pharmaceuticals; Dosage formulation in the nature of pharmaceutical drug development services, pharmaceutical products development using Multi-Factor-At-a-Time strategies; Dosage formulation and analysis in the nature of pharmaceutical drug development services, pharmaceutical products development, testing services for pharmaceuticals, namely, developing different dose and delivery systems in the nature of oral solids in the nature of tablets, capsules, gummies, candy, pastes, powder blends; oral semi-solids in the nature of soft-gels, gels in the nature of oral liquids, tincture, syrup, sprays, sublingual sprays, and oral care liquids, vitamins, mineral drinks, and topical formulations such as dermal and transdermal creams, gels, lotions, and serums; Qualitative and quantitative analysis of key active compounds in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products; Dosage and dose analysis in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify potency and strength of dosage; Forced degradation analysis of pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify stability indication of the dosage, the shelf life determination
Goods and Services
Dosage formulation development and analysis services, namely, pharmaceutical drug development services, testing services for pharmaceuticals, pharmaceutical products development, laboratory research services relating to pharmaceuticals, and testing, inspection or research of pharmaceuticals; Dosage formulation in the nature of pharmaceutical drug development services, pharmaceutical products development using Multi-Factor-At-a-Time strategies; Dosage formulation and analysis in the nature of pharmaceutical drug development services, pharmaceutical products development, and testing services for pharmaceuticals, namely, developing different dose and delivery systems in the nature of oral solids in the nature of tablets, capsules, gummies, candy, pastes, powder blends, oral semi-solids in the nature of soft-gels, gels in the nature of oral liquids, tincture, syrup, sprays, sublingual sprays, and oral care liquids, vitamins, mineral drinks, and topical formulations in the nature of dermal and transdermal creams, gels, lotions, and serums; Scientific research services in the nature of qualitative and quantitative analysis of key active compounds in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products; Pharmaceutical research services in the nature of dosage and dose analysis in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify potency and strength of dosage; Scientific research services in the nature of forced degradation analysis of pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify stability indication of the dosage and the shelf life determination
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2019-08-21
Primary Code
042
Current Trademark Owners
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Correspondences
Name
Francis John Ciaramella, Esquire
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2019-08-21 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2019-09-27 | ASSIGNED TO EXAMINER |
2019-10-02 | NON-FINAL ACTION WRITTEN |
2019-10-02 | NON-FINAL ACTION E-MAILED |
2019-10-02 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2020-04-02 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2020-04-09 | ASSIGNED TO LIE |
2020-04-17 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2020-04-17 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2020-04-21 | SUSPENSION LETTER WRITTEN |
2020-04-21 | LETTER OF SUSPENSION E-MAILED |
2020-04-21 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
2020-10-21 | SUSPENSION INQUIRY WRITTEN |
2020-10-21 | INQUIRY TO SUSPENSION E-MAILED |
2020-10-21 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
2021-04-20 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
2021-04-22 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-04-22 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-05-07 | NON-FINAL ACTION WRITTEN |
2021-05-07 | NON-FINAL ACTION E-MAILED |
2021-05-07 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2021-11-05 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-11-05 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-11-06 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-11-30 | EXAMINERS AMENDMENT -WRITTEN |
2021-11-30 | EXAMINERS AMENDMENT E-MAILED |
2021-11-30 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2021-11-30 | EXAMINER'S AMENDMENT ENTERED |
2021-11-30 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2021-12-15 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2022-01-04 | PUBLISHED FOR OPPOSITION |
2022-01-04 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |